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1. Introduction 
 
1.1 Acromegaly 
 
1.1.1 Definition and history 
 
Acromegaly is a rare endocrine disorder resulting from overproduction of growth 
hormone (GH) (Ayuk & Sheppard, 2006). In general, somatotrophic pituitary 
adenomas are the cause for uncontrolled production of growth hormone. As a 
consequence, this leads to the typical clinical picture of acromegaly, which is mainly 
characterized by above average growth of extremities and acres: fingers, toes, nose, 
chin and ears. Clearly recognizable are the typical features of acromegaly in the 
portrait of American actor Richard Kiel (1939-2014) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:	Richard Kiel (1939-2014): 
Was an American actor. He became 
known for his role as „Jaws“ in the 
James Bond movies.	
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In 1886, the disease was described for the first time as “acromegaly” by the French 
neurologist Pierre Marie (1853-1940) and for this reason, it is sometimes called 
Pierre-Marie-Syndrome. Furthermore, he used the greek words akron- (“extremity”) 
and mega (“large”) to describe the typical clinical findings (Carroll PV et el. 2016).  
However, clinical descriptions of the disease already existed before (de Herder, 
2009). 
 
In 1909, Harvey Cushing observed clinical remission in patients with acromegaly 
after performing hypophysectomy. Therefore, he suspected the cause of acromegaly 
must be an overproduction of a hormone which is produced in the pituitary and is 
responsible for growth (Mammis, Eloy, & Liu, 2010). 
 
1.1.2 Epidemiology 
 
The epidemiology of acromegaly is well described and the disease has an incidence 
of 0.3 cases in a population of 100,000 in one year (Tjornstrand et al., 2014). 
Typically, patients are affected in the fourth and fifth life decade (Fernandez, 
Karavitaki, & Wass, 2010). Patients with acromegaly have an increased mortality rate 
compared to the normal population. However, this can be reduced to normal values 
by lowering the GH-values through therapy (Bates, Van't Hoff, Jones, & Clayton, 
1993). Especially complications of the cardiovascular and respiratory system are 
responsible for increased mortality in patients with acromegaly (Colao, Ferone, 
Marzullo, & Lombardi, 2004). Although the majority of diagnoses are made in middle-
aged patients, there is also a large number of younger patients. These younger 
patients tend to develop more aggressive tumors with higher growth hormone 
concentrations (Holdaway & Rajasoorya, 1999).  
 
1.1.3 Pathophysiology 
 
Usually, Acromegaly presents itself with a growth-hormone secreting tumor that 
originates from somatotrophic cells in the pituitary gland (Melmed, 2006). This leads 
to increased basal growth hormone concentrations due to uncontrolled continuous 
release of GH (Hartman et al., 1990). The vast majority of somatotrophic tumors 
(>90%) develop sporadically but some hereditary forms of somatotroph adenomas 
associated with familial isolated pituitary adenomas (FIPA), X-LAG syndrome, 
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multiple endocrine neoplasia type 1 (MEN 1) and other types of hereditary endocrine 
syndromes are also known.  
 
The pathogenesis of somatotroph adeomas is still poorly understood. About 40% of 
patients with sporadic somatotroph adenomas are bearing mutations of the G protein 
alpha chain of the stimulating G protein, which leads to continuous activation of the 
GHRH receptor-dependent signaling cascade and results in increased, GHRH-
independent GH synthesis and secretion (Landis et al., 1989; Melmed, 2006). 
 
The increased production of GH is finally responsible for augmented serum levels of 
Insulin-like growth factor 1 (IGF-1), which mediates the growth-promoting effects of 
GH to peripheral organs (Laron, 2001). The result are anabolic and growth-promoting 
metabolic effects which consequently causes the typical clinical appearance of 
acromegaly (Melmed, 2006). 
 
1.1.4 Growth hormone 
 
GH is a polypeptide that is formed in the pituitary gland and is composed of 191 
amino acids. Besides that, it contains two disulfide bridges and has a molecular 
weight of 22 kilodaltons (Li & Dixon, 1971).  
GH acts by binding to somatotropin receptors that can be found in a variety of tissues 
(Postel-Vinay & Finidori, 1995). Especially in the liver, it stimulates the formation of 
Insulin-like growth factor (IGF-1).  
 
GH has anabolic effects on bone and mineral metabolism (Tritos & Klibanski, 2016). 
It can also cause abnormalities in the cardiovascular system (Colao, 2008). In 
addition, GH increases the blood glucose level by stimulating glycogenolysis and it 
has a fat-reducing effect by stimulating lipolysis (Ghanaat & Tayek, 2005; Sakharova 
et al., 2008).  
 
Moreover it has been clearly established that the anabolic and growth-promoting 
metabolic effects are not determined directly by GH but are mainly mediated 
indirectly by IGF-1 (Laron, 1999).  
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Due to regulatory effects of GH on glucose metabolism, hypoglycaemia can lead to 
compensatory hyperglycaemia and in case of permanently pathologically increased 
releases of GH, this can lead to insulin resistance and thus to diabetes mellitus 
(Holly, Amiel, Sandhu, Rees, & Wass, 1988). IGF-1 modulates insulin receptors and 
can stimulate beta-cells of the pancreas to increase insulin secretion. Therefore, 
pathologically high levels of IGF-1 can lead to disorders of beta-cell function and thus 
to insulin resistance. (Moller et al., 1991). 
 
1.1.4.1 Regulation of GH synthesis 
 
The gene for growth hormone is located on the long arm of chromosome 17 (q22-
q24) and transcribed exclusively in the somatotropic cells of the pituitary anterior lobe 
(Miyachi, Yakushiji, & Terazono, 1993). 
 
Growth hormone production is stimulated by GH releasing hormone (GHRH). GHRH 
consists of 40 amino acids and is formed in the hypothalamus. Via the pituitary portal 
system GHRH is transported into the pituitary gland (Bloch et al., 1983). In the 
pituitary gland, it stimulates somatotropic cells to secrete GH in pulsatile rhythm 
(Cataldi et al., 1994) (Figure 2). Secretion increases during sleep und puberty 
(Minuto et al., 1982).  
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Figure 2: Control loop and effect of GH and IGF-1 on the metabolism. GH is 
produced in the pituitary after stimulation by GHRH. It stimulates the formation of 
IGF-1 in the liver which has anabolic effects on bone and muscle. GH inhibits its 
secretion through a negative feedback mechanism. 
 
 
Somatostatin (SMS) represents the counterpart to GHRH and inhibits secretion of 
GH (Ge, Tsagarakis, Rees, Besser, & Grossman, 1989). SMS (somatostatin) is a 
peptide hormone synthesized in the pancreas as well as in the gastrointestinal tract 
and hypothalamus. In the pituitary, SMS acts as an inhibitor on somatotroph cells 
and suppresses growth hormone secretion (Brazeau, Rivier, Vale, & Guillemin, 
1974). It also inhibits release of glucagon and insulin in the pancreas (Strowski, 
Parmar, Blake, & Schaeffer, 2000). The distribution of somatostatin is regulated in 
the cells of the hypothalamus by the second messenger cAMP, which activates the 
protein kinase A (PKA). PKA phosphorylates the intracellular transcription factor 
CREB, which binds to the promoter of the somatostatin gene and the expression of 
the hormone follows (Montminy & Bilezikjian, 1987).  
 
Insulin-like growth factor 1 inhibits the GH release by a negative feedback 
mechanism on pituitary level. IGF-1 causes enhanced SMS synthesis in the 
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hypothalamus, which in turn suppresses GH secretion (Berelowitz et al., 1981).  
IGF-1 has 70 amino acids and is similar in structure to insulin. It is primarily produced 
in the liver in response to GH (Daughaday & Rotwein, 1989).  
 
Hypoglycemia, physical exertion and stress have an excitatory effect on GH 
secretion (Greenwood & Landon, 1966; Jaffe, Huffman, & Demott-Friberg, 1999).  
Apart from that, serotonin, testosteron and dopamine stimulate GH secretion and 
besides IGF-1, hyperglycemia, hyper- and hypothyroidism, fatty acids, nicotine and 
age have an inhibitory effect on GH secretion (Root & Diamond, 2000). 
 
Ghrelin, a peptide that is formed in the hypothalamus and gastrointestinal tract has a 
stimulating effect on GH release (Tannenbaum, Epelbaum, & Bowers, 2003) 
 
1.1.5 Diagnostics 
 
On average, diagnosis of acromegaly is made only between six and ten years after 
onset of the disease (Holdaway & Rajasoorya, 1999). Late diagnoses usually affect 
patients older than 50 years and less frequently younger patients under 30 years of 
age (Nabarro, 1987).  
Due to typical clinical findings, acromegaly is often a visual diagnosis of an 
experienced endocrinologist. In order to make the diagnosis, it is also very important 
to get blood samples to determine GH and IGF-1 values. Here it is of special 
importance that not only GH values are determined, because GH serum levels alone 
are not sufficient since they fluctuate during the day (Winer, Shaw, & Baumann, 
1990). For this reason, IGF-1 values should always be checked as well because IGF-
1 directly correlates with GH activity and is elevated in most initial diagnoses 
(Barkan, Beitins, & Kelch, 1988).  
Another cornerstone of the diagnosis is the oral glucose tolerance test (oGTT). With 
an oGTT, measurements of the suppression of GH secretion can be performed. After 
completion of the oGTT, acromegaly can be diagnosed if GH is not suppressed to < 
1 µg/L after a 2 hour oGTT (Freda, Post, Powell, & Wardlaw, 1998).  
Eventually, to confirm the suspected diagnosis of Acromegaly, neuroradiological 
imaging with CT or MRI is necessary. MRI is the method of choice in radiological 
detection and characterization of pituitary adenomas and the goal is to find out its 
size, location and extent (Rumboldt, 2005) (Figure 3).  
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Figure 3: Pituitary tumor in MRI image: Macroadenoma with compression of optic 
chiasm. 
(https://en.wikipedia.org/wiki/Acromegaly#/media/File:Acromegaly_pituitary_macroad
enoma.JPEG) 
 
Here the classification of Hardy is used to measure the size of the tumor. According 
to this classification, tumors < 10mm are microadenomas and tumors 10 > mm are 
macroadenomas. It is important to determine tumor volume because it correlates with 
visual field defects (Kan, Kan, Atmaca, Atmaca, & Colak, 2013). Visual field defects 
can be detected with a perimetry test. 
 
1.1.6 Clinical presentation 
 
It is often observed in younger patients that when overproduction of growth hormone 
occurs before the end of length growth, then gigantism can result (Melmed, 2006). 
These young patients can reach body sizes of more than two meters (Creo & Lteif, 
2016). In adults, epiphyseal plates are already closed and length growth is no longer 
possible. 
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Figure 4: Fedor Machnow (1878-1912): He grew up to a height of 2.39 m. He 
travelled Europe around 1900, and the USA to exhibit his unusual size at fairs. 
https://de.wikipedia.org/wiki/Riesenwuchs#/media/File:Fedor_Machnow_01.jpg 
 
 
 
Therefore, in adults, symptoms are particularly evident by changes in face, skeleton 
as well as organs, and a gradual development of the symptoms takes place with a 
diagnosis only after about seven to ten years after onset of the disease (Rajasoorya, 
Holdaway, Wrightson, Scott, & Ibbertson, 1994).  
Direct effects of the tumor can be visual loss, headache, cranial nerve paralysis, 
hypothyroidism, hypogonadism and hypocortisolism.  
Overproduction of GH/IGF-1 can lead to several systemic effects in the form of soft 
tissue and skin changes, enlargement of the extremities, soft tissue swelling, 
prognathism, carpal tunnel syndrome and hyperhidrosis (Colao et al., 2004).  
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Hormone excess can also lead to respiratory and cardiovascular complications 
(Colao et al., 2004). Respiratory complications, such as sleep apnea and lung 
diseases, are caused by the effects of GH and IGF-1 and can increase mortality in 
those patients (Fatti, Scacchi, Pincelli, Lavezzi, & Cavagnini, 2001). Cardiovascular 
symptoms may be arterial hypertension, valvular disease, arrythmias, and 
cardiomyopathy (Giustina et al., 2003).  
 
Other typical clinical features are complications in metabolism, such as diabetes 
mellitus and insulin resistance, as well as alterations of bones and joints, in form of 
increased articular cartilage thickness, arthropathy and carpal tunnel syndrome 
(Colao et al., 2004). Especially arthropathy is a common complication of acromegaly 
and can lead to invalidity (Claessen et al., 2017).  
 
Moreover, endocrine disorders such as hypogonadism and hyperprolactinaemia may 
appear  (Colao et al., 2004). In women there may also be amenorrhea or 
galactorrhea, and in men, libido or potency disorders (Franks, Jacobs, Martin, & 
Nabarro, 1978; Goldman & Klinges, 1989). In addition, adrenal gland disorders can 
occur and the number of thyroid pathologies in patients with acromegaly is high 
(Roginsky, Shaver, & Christy, 1966).  
 
Many patients with pituitary adenomas have lower quality of life index, poorer sleep 
quality and increased risk of depression (Leistner et al., 2015). For this reason, 
depression and feelings of inferiority can also occur over the course of the disease 
(Geraedts et al., 2014). 
 
Epidemiological studies showed an increased risk for the development of cancer in 
patients with acromegaly (Holdaway & Rajasoorya, 1999), especially for cancer in 
the gastrointestinal tract (Colao et al., 2004).  
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1.1.7 Prognosis  
 
Compared to the normal population, acromegaly has a detrimental effect on well-
being and mortality risk. The determining factor of outcome are serum GH levels after 
therapy (Rajasoorya et al., 1994).  
The reason for increased mortality risk is not only the tumor itself, but also 
cardiovascular diseases caused by acromegaly (Wright, Hill, Lowy, & Fraser, 1970). 
Another factor that can determine the prognosis is artropathy and if it cannot be 
prevented in the initial stages, morbidity and functional impairment increases. In 
general, if there is no proper therapy for acromegaly, morbidity and mortality rates 
increase (Colao et al., 2004). 
 
 
1.2 Diabetes mellitus type 2 
 
In patients with acromegaly, disturbances of glucose metabolism are frequently 
manifested. In approximately 20-30% of patients with acromegaly, type 2 diabetes 
mellitus may occur, with age, BMI and hypertension being the most significant risk 
factors (Fieffe et al., 2011; Giustina et al., 2003; Niculescu, Purice, & Coculescu, 
2013).   Patients with acromegaly who are additionally affected by type II diabetes, 
have a poorer prognosis. While GH has an inhibitory effect on insulin and 
downregulates insulin sensitivity, IGF-1 increases insulin sensitivity, however the 
effect of GH is stronger and often leads to diabetes mellitus (Clemmons, 2002; Colao 
et al., 2004). 
 
In a diabetic, typical symptoms of acromegaly can indicate the underlying disease. 
Fatigue, thirst, polydipsia, weight loss, itching, insomnia and restlessness are 
common signs of diabetes mellitus. In addition, there may be specific symptoms of 
the kidney, eye, skin (wound healing disorders, etc.), immune system and nervous 
system (polyneuropathy etc.).  
 
Weight management and lifestyle modification are the primary therapeutic options for 
diabetes mellitus type 2. Beneficial effects can be achieved through exercise and 
diet. Risk factors such as smoking, hypertonus, obesity and fat metabolism disorders 
should be avoided. In type 2 diabetes, weight loss is the most effective treatment 
	 19	
option. However, since weight control is difficult, monotherapy with Metformin is 
usually initiated. If the therapeutic target is not achieved, one or more oral 
antidiabetics (for example gliptins, glinides, sulfonylureas) or insulin can be added in 
addition to metformin.  
 
 
 
1.2.1 Metformin 
 
Metformin is an oral antidiabetic drug which reduces insulin resistance, indirectly 
lowers insulin levels and is mainly used in patients with type 2 diabetes mellitus. The 
effect of metformin is based on the reduction of hepatic glucose production by 
inhibiting gluconeogenesis and lipogenesis (Viollet et al., 2012). This is achieved by 
inhibiting complex I of the mitochondrial respiratory chain and thereby creating an 
energy deficit within the cell. This results in a direct inhibition of gluconeogenesis and 
an activation of the intracellular energy sensor AMPK. Consequently there is a 
reduced transcription of CREB which is responsible for the intranuclear expression of 
the gluconeogenesis program (Viollet et al., 2012). By activating AMPK, Sirt1 is also 
activated and leads to inhibition of gluconeogenesis (Caton et al., 2010). The 
activation of AMPK by metformin and the ensuing inhibition of CREB is likely 
exclusive to hepatocytes, since there are opposing effects in other body cells, which 
leads to the assumption that metformin also acts through other intracellular 
processes (Faggi, Giustina, & Tulipano, 2017; Viollet et al., 2012) (Figure 5).  
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Figure 5: Effect of Metformin on gluconeogenesis in hepatocytes. 
 
Furthermore, metformin is believed to increase absorption of glucose in the intestine, 
as well as in muscle cells (Natali & Ferrannini, 2006). Side effects of therapy with 
Metformin may be gastrointestinal disorders, such as nausea and diarrhea. However, 
if doses of metformin are reduced, these side effects usually subside (DeFronzo & 
Goodman, 1995). Lactate acidosis is a rare but feared side effect of treatment with 
Metformin. This can take place in hypoperfusion and hypoxia by cardiovascular, 
pulmonary, hepatic or renal diseases and is characterized by an increased blood 
lactate concentration (> 45 mg / dL), a reduced blood pH (<7.35) and an increased 
anion gap (Oliva, 1970; Salpeter, Greyber, Pasternak, & Salpeter, 2010; Stang, 
Wysowski, & Butler-Jones, 1999).  
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1.3 Treatment of acromegaly 
 
Primary goal of therapy in acromegaly is reduction of GH and IGF-1 values to normal 
ranges (Giustina et al., 2000). Biochemical control of acromegaly is defined 
according to following criteria: 1) Normalization of basal GH below 2.5 ng / mL, 2) 
suppression of GH <1 ng / mL in the oGTT (or < 0.5 ng / mL), 3) IGF-1 within age- 
and gender-specific norm ranges (Brabant, 2003; Freda, 2003; Giustina et al., 2000). 
In patients receiving therapy with somatotropin antagonists, only IGF-1 values are 
used for control (Lim & Pullan, 2005). 
In acromegaly, surgery is the first treatment for most patients. Alternatively, drug 
therapy with dopamine agonists, somatostatin analogues or GH receptor antagonists 
is used to block the action or production of GH. Drug therapy can be administered 
preoperatively or postoperatively, and a combination of two drugs is also possible 
depending on each individual case. Postoperatively or in patients who do not tolerate 
a drug therapy, radiotherapy can be performed (Melmed, 2006) (Figure 6). 
 
Figure 6: Therapeutic possibilities. 
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The aim of therapy is biochemical and clinical control of the disease. In addition, 
pituitary function should remain intact and there should not be any injury of the optic 
chiasm during surgical treatment. If pituitary insufficiency occurs, substitution with the 
corresponding hormone should be initiated. 
 
1.3.1 Surgery 
 
Transsphenoidal surgery represents the first-line treatment in most patients with 
acromegaly.  
 
It is indicated for growth-hormone-secreting microadenomas, as well as for 
decompressions of surrounding tissues, especially the optic tract (Melmed, 2006). 
Within one hour after surgery, normalization of growth hormone serum levels is 
possible. For larger macroadenomas and invasive tumors, however, complete 
resection is rarely possible (Ben-Shlomo & Melmed, 2008).  
 
In transsphenoidal surgery, the surgeon reaches the sphenoid sinus via the nasal 
cavity, where the hypophysis is adjacent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Success in transsphenoidal surgery depends on tumor size, invasiveness of the 
tumor, and experience of the surgeon (Freda, 2003). Furthermore, as a result of 
surgery, it was observed in some patients that it had a positive effect on the glucose 
Figure 7: Transsphenoidal Surgery. 
(http://www.newhealthadvisor.com/pituitary-
adenoma-surgery.html) 
. 
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metabolism (Helseth et al., 2016). However, in about 10 % of cases, hypopituitarism 
may occur postoperatively (Melmed, 2006). 
 
 
1.3.2 Radiotherapy 
 
If not all tumor residues could be removed during surgery, postoperative radiation is 
considered. In case of intolerance of medical treatment or at the request of the 
patient, radiotherapy can be initiated. Radiotherapy can be done with Cyberknife, 
Gammaknife or in conventional stereotactic irradiation. In approximately 60 % of 
these patients, pituitary insufficiency occurs within 5-10 years, which requires 
treatment (Melmed et al., 2002).  
 
 
1.3.3 Hypopituitarism 
 
In some patients pituitary insufficiency may occur. After transsphenoidal surgery 
approximately 30 % of patients develop hypopituitarism (Colao et al., 2006) and in 
the space of 10 years after radiotherapy 50 % of patients are affected by it (Melmed, 
2006). 
For diagnosis of hypopituitarism, measurements of hormone levels are sufficient. 
However, if there is a lack of growth hormone or corticotropin, a stimulation test is 
necessary (Schneider, Aimaretti, Kreitschmann-Andermahr, Stalla, & Ghigo, 2007).  
Depending on the course of the disease, partial or complete hypopituitarism may 
occur. In the case of pituitary anterior lobe insufficiency, deficiency of the 
adenohypophysis with a reduced production of TSH, ACTH, GH etc. can occur. 
Depending on the affected axis, different symptoms and reduced Quality of Life 
(QoL) may follow, and therapy should be individualized by hormone replacement, 
taking into account possible interactions (van Aken & Lamberts, 2005). 
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1.3.4 Pharmacological therapy 
 
 
1.3.4.1 Dopamin agonists (DA) 
 
In patients with acromegaly, dopamine agonists have an inhibitory effect on GH 
secretion. There are many different dopamine subtypes, organized according to their 
structural homology, e.g. D1,5-agonists and D2,3,4-agonists. Bromocriptine was the first 
dopamine agonist used in acromegaly. Although, bromocriptine achieved good 
effects in controlling acromegaly, it lacked potency and had several side effects 
(Jaffe & Barkan, 1992). 
Today cabergoline a more potent, second-generation D2 receptor agonist is used as 
a therapeutic standard, with significantly fewer side effects. Cabergoline is 
comparatively low priced and can be administered orally (Colao et al., 1997). 
Cabergoline can be considered in patients with GH-prolactin secreting pituitary 
adenomas (Muller & Van Der Lely, 2004). In patients, in which therapy with 
somatostatin analogues is ineffective, cabergoline can normalize IGF-1 values in 40-
50 % of patients (Kuhn & Chanson, 2017). Presumably, therapy with cabergoline is 
beneficial in patients with disturbed glucose tolerance, which is the precursor of 
diabetes mellitus (Gibson, Karmally, McMahon, Wardlaw, & Korner, 2012).  
 
 
 
 
1.3.4.2 Somatotropin antagonists 
 
Another option to treat acromegaly is pegvisomant, a subcutaneously injected growth 
hormone receptor antagonist. The monotherapy with pegvisomant is performed in 
most cases only when surgery, radiotherapy or somatostatin analogues were not 
successful (Giustina et al., 2011).  
Known side effects of the therapy with pegvisomant are reactions at the injection 
sites, nausea, peripheral edema, chest pain, paresthesia and disorders of glucose 
metabolism. 
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Long-term studies showed an efficacy of 85 % after therapy with pegvisomant, but in 
some cases there was an increase in transaminases as well as an increase in tumor 
volume (Hodish & Barkan, 2008).  
 
1.3.4.3 Somatostatin analogues 
 
Somatostatin analogues (SSA) are the mainstay in targeted hormonal treatment of 
acromegaly. Somatostatin (SMS) inhibits the release of many hormones, e.g. GH, 
insulin, glucagon and TSH (Roelfsema & Frolich, 1991). Moreover, it has an 
inhibitory effect on the peristalsis of the stomach (Izumi, Honda, Tsuchiya, Ueda, & 
Hatano, 1980), gastric acid secretion and the exocrine secretion of pancreatic 
enzymes (Abdu, Hicks, Hennig, Allen, & Grundy, 2002). It also reduces blood 
pressure via the splanchnic system.  
 
Since the 1980s it is used as a primary, pre- or postoperative therapy of acromegaly. 
Octreotide (sandostatin) and lanreotide (somatulins) act on the receptor subtypes 2 
and 5 (SSTR2, SSTR5), which are responsible for inhibition of growth hormone 
(Jiang et al., 2011).  
 
Until recently, somatostatin had to be administered subcutaneously daily. Today, only 
one application every month is possible through depot preparations (somatuline, 
autogel, Sandostatin LAR). The possibility of oral administration of somatostatin 
analogues in the therapy of acromegaly is currently under discussion (Biermasz, 
2017) as a recent study has shown that patients who have switched from injection 
therapy to oral therapy have demonstrated adequate efficacy with regard to 
controlled GH and IGF-1 levels (Melmed et al., 2015). 
 
Whether SSA can be administered depends on therapy resistance and tolerability of 
the therapy. The most common side effects include digestive disorders, gall stones 
and reactions at the injection site (Chakravarty, Ajmani, Manchanda, Kulshreshtha, & 
Chopra, 2012). Moreover, a deterioration of glucose metabolism was observed 
during preoperative SSA treatment (Helseth et al., 2016).  
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SSA have a very good response rate in acromegaly and provide an effective 
treatment option (Vance & Harris, 1991). It has also been shown that SSA can 
alleviate symptoms such as headache in patients with acromegaly in the shortest 
time possible (Levy, Bejon, Barakat, Goadsby, & Meeran, 2003). 
 
Optimization of surgical results was achieved by preoperative treatment with SSA 
(Bevan et al., 2002; Losa et al., 2006). Moreover, a positive effect on tumor 
shrinkage has been observed in several studies both in macro- as well as in 
microadenomas (Bevan, 2005; Losa et al., 2006). 
 
The exact mechanisms of how SSA causes a reduction in tumor cells in pituitary 
adenomas is not yet fully understood. It is known, however, that SSA has an 
antiproliferative effect on pituitary tumor cells via the tumor suppressor gene Zac1 
(Theodoropoulou et al., 2006).  
 
Pasireotide (SOM230) is a new SSA which has a high affinity to the somatostatin 
receptor type 5 (SSTR5) and is therefore used as a means of second choice in 
acromegaly. In patients with octreotide resistance, it can suppress GH (van der Hoek 
et al., 2004). In patients who do not achieve biochemical control in a first-line therapy 
with somatostatin analogues, Pasireotide could become standard medication 
because of its efficacy (Gadelha et al., 2014) 
 
 
1.3.4.4 Somatostatin analogue resistance 
 
Although SSA are the mainstay in medical therapy of acromegaly, many patients are 
resistant to their anti-secretory and tumor shrinking effects. The efficacy of SSA 
treatment is dependent on age, gender, initial GH and IGF-1 levels, tumor size and 
the expression of somatostatin receptors (Colao, Auriemma, Lombardi, & Pivonello, 
2011).  
A possible marker for the efficacy of the therapy could be the transcription factor 
Zac1, whose immunoreactivity correlates positively with tumor shrinkage and 
reduced IGF-1 levels after SSA therapy and was not affected by age at diagnosis, 
gender or duration of SSA treatment (Theodoropoulou et al., 2009). 
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1.4 Aim of the study 
 
Treatment of somatotroph pituitary tumors by transspenoidal surgery and/or 
treatment with somatostatin analogues (SSA) is the standard therapy for acromegaly. 
During therapy, a considerable proportion of the acromegalic patients develops 
partial pituitary insufficiency and thus receives corresponding hormone replacement 
therapy. In up to 30% of the patients with acromegaly the disturbed glucose 
metabolism may finally lead to type 2 diabetes mellitus which is treated by the anti-
diabetic drug metformin. As acromegalic patients respond differently to SSA 
treatment the question arises whether hormone replacement or metformin treatment 
has an influence on the success of SSA therapy.  
To address these questions the acromegalic patient cohort of the NeoExNET 
database was used and statistically screened for correlations between the degree of 
pituitary insufficiency and SSA treatment response. Moreover it was approved, 
whether anti-diabetic metformin treatment in acromegalic patients had an influence 
on SSA responsiveness. The effect of metformin on SSA treatment was not only 
studied in the NeoExNET cohort but also in vitro in primary cell cultures of human 
somatotroph tumors and in the lactosomatotroph rat pituitary tumor cell line. 
In sum the aim of the study was to clarify the influence of hormone replacement 
therapy and metformin treatment on the efficacy of SSA therapy in acromegaly.     
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2. Materials & Methods 
 
2.1 Patients  
 
2.1.1 Database NeoExNetM  
 
Retrospective data analysis with patient data from the NeoExNetM was performed. 
NeoExNetM is a database for neuroendocrine tumors in Munich. The following clinics 
in Munich are involved: Medical Clinic Center in Zimssensstraße 1, Medical Clinic 
and Polyclinic II in Marchionistrasse, as well as the Max Planck Institute for 
Psychiatry in Munich. Only patients with neuroendocrine disorders were added to the 
NeoExNetM. These included patients with prolactinoma, Cushing's disease, clinically 
non-functioning adenomas (NFPA) and acromegaly. In this study, only data from 
acromegaly patients were used (Table 1).  
 
Table 1: Patient data from NeoExNetM 
Base data • Name 
• Gender 
• Date of Birth 
• Address 
• Register assignment 
(Acromegaly, M.Cushing, NFPA, 
prolactinoma) 
• Consent form 
Comorbidities Cardiovasular 
• Arrhythmias 
• Cardiomyopathy 
• Cerebrovascular diseases 
• Arterial hypertension 
• Coronary heart disease  
• Myocardial infarction 
Metabolic 
• Diabetes mellitus 
• Pathological glucose tolerance 
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• Pituitary insufficiency 
• Diabetes insipidus 
Respiratory 
• Sleep apnea syndrome 
Anamnesis • Patient history 
• Family history 
• Drug history other than 
acromegaly 
Symptoms • Growth of hands / feet 
• Soft tissue swelling 
• Carpal tunnel syndrome 
• Arthralgia 
• Fatigue 
• Headache 
• Paraesthesia 
• Hyperhidrosis 
• Visual impairment 
• Cycle malfunctions (Gyn.) 
• Libido and potency loss 
• Depression 
Physical examination • Height (cm) 
• Body weight (kg) 
• BMI 
• Waist and hip circumference 
• Blood pressure (mmHg) 
• Pulse 
Laboratory General Laboratory 
• Leukocytes, erythrocytes, 
hemoglobin, hematocrit, MCV, 
MCH, MCHC, thrombocytes, 
eosinophilia 
• Sodium, potassium, creatinine, 
GFR, urea, calcium, phosphate, 
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GOT, GPT 
• Fasting Glucose, HbA1c, fasting 
Insulin 
• Total cholesterol, triglycerides, 
HDL, LDL, vitamin B12, CRP 
• fT3, fT4, TSH, TPO-AK, 25-OH-
Vit. D3, PTH 
Urine Stix, urine quantitatively 
OGTT (oral glucose tolerance test) 
• fasting glucose / insulin 
• glucose / insulin after 60 min 
• glucose / insulin after 120 min 
Hormonal diagnostics 
• Prolactin 
• Cortisol 
• Stimulated cortisol 
• LH, FSH 
• Testosterone, estradiol 
• GH basal, GH nadir in OGTT, 
Stimulated GH 
• IGF-1, IGF-BP3 
Imaging Pituitary 
• MRI/CT 
• Contrast medium 
• Valuation 
• Max. tumor size 
Imaging bone density 
Echocardiography 
Tyhroid sonography 
Range of vision 
Device diagnostics 
Therapy Medicines 
• Somatostatin analogues (SSA) 
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• Dopaminagonists 
• Pegvisomant 
• Other Medicines 
Surgery 
• Date 
• Number of surgeries 
• Type of surgery 
• Surgery Center 
• Histology 
Radiation 
• Date 
• Type of radiation 
• Place of radiation 
 
Outcome • Clinically controlled 
• Biochemically controlled 
• Change of tumor size 
 
 
 
 
2.1.2 Data collection 
 
Of 49 patients with acromegaly, 36 patients received therapy with somatostatin 
analogues at any time. In order to assess the effect of SSA-therapy, various 
parameters were compared during initial diagnosis and during the course of the 
disease. These contained the GH and IGF-1 values in the initial diagnosis and after 
somatostatin analog therapy. We then calculated the difference between the two 
values and checked whether SSA therapy resulted in a normalization of the values. 
The difference between the two values was then calculated and checked whether 
SSA therapy resulted in a normalization of the values. In addition, pituitary adenoma 
size was reported. We classified the tumor size according to Hardy, where pituitary 
adenomas are subdivided into 4 grades: grade I for microadenomas (<10 mm in 
diameter), grade II for macroadenomas (> 10 mm in diameter) that could reach the 
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suprasellar region but no bony structures, Grade III for locally invasive tumors, and 
grade IV for large invasive tumors that may affect the hypothalamus or cavernous 
sinus. We also investigated the presence of pituitary insufficiency. It was examined 
whether this was an insufficiency of the corticotrophic, thyreotrophic, gonadotrophic 
or somatotrophic function. Combinations of the malfunctions were also considered. 
Information on the therapy of pituitary insufficiency was taken from the NeoExnetM.  
Differentiation was made here between corticosteroid therapy in the event of failure 
of the corticotrophic function, testosterone / estradiol therapy in the event of failure of 
the gonadotropic function, thyroxine therapy in the event of a failure of the 
thyreotropic function or growth hormone therapy in the case of somatotropic 
insufficiency. 
Furthermore, NeoExnetM provided information on whether metformin therapy was 
performed in the acromegalic patients with diabetes mellitus. 
 
 
2.1.3 Data processing and statistical evaluation  
 
Data processing and statistical evaluation of the results were carried out using SPSS 
(Statistical Package for Social Sciences).  
To assess the contribution of both surgery and SSA suppletion on pituitary 
insufficiency (dichotomous), a binary logistic regression analysis was performed. The 
model carried an additional correction for age, gender, disease duration and tumor 
size, as well as the main variables of interest surgery (dichotomous) and SSA 
(dichotomous). A forced entry method was used.  
In addition, a logistic regression was performed to investigate whether there were 
interactions between therapy with somatostatin analogues and treatment of 
hypopituitarism.  
To assess the contribution of treatment modalities to the outcome change in IGF1, a 
linear regression analysis was used using three blocks. Block 1 contained: age, 
gender, disease duration and tumor size. Block 2 contained the treatment modalities 
/ comorbidities (dichotomous): somatostatin analogues, corticosteroid 
supplementation, testosterone / estrogen supplementation, growth hormone 
supplementation, thyroid hormone supplementation and pituitary insufficiency. Block 
3 contained the main variable of interest (dichotomous): metformin application. A 
forced entry method was used for all blocks. 
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In this study, P-values with p < 0.05 are considered statistically significant and P-
values with p < 0.01 as highly significant. For P-values with p < 0.1, one speaks of a 
trend towards statistical significance.  
In the case of a variable inflation factor VIF < 1, predictors do not correlate with one 
another; in the case of 1 < VIF > 5, the predictors correlate moderately with one 
another and with a VIF > 5 predictors strongly correlate with each other. 
 
 
2.2 In vitro studies 
 
2.2.1 Reagents 
 
Table 2: Reagents. 
Product Manufacturer 
Dulbecco’s modified Eagle medium 
(DMEM) 
Invitrogen Corp. (Paisley, Scotland, UK) 
Dimethyl sulfoxide (DMSO) Sigma (St. Luis, MO, USA) 
Fetal Scalf Serum (FCS) Gibco (Karlsruhe, Germany) 
L-Glutamin Biochrom AG (Berlin, Germany) 
Metformin Sigma (St.Luis. MO, USA) 
ONPG Sigma (St. Luis, MO, USA) 
Amphotericin B Biochrom AG (Berlin, Germany) 
Penicillin+Steptomycin-Mix Biochrom AG (Berlin, Germany) 
Phosphate based buffer (PBS) Life Technologies (Paisley, Scotland, 
UK) 
Resveratrol Calbiochem (Darmstadt, Germany) 
Superfect Qiagen (Hilden, Germany) 
Trypsin Sigma (St.Luis. MO, USA) 
WST-1 assay Roche (Mannheim, Germany) 
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2.2.2 Solutions 
 
 
 
Table 3:	Solutions. 
Solution Composition 
HDB+ Buffer Glukose                              : 10 mM 
NaCl                                   : 137 mM 
KCl                                      : 5 mM 
Na2HPO4                            : 0.7 mM 
HEPES                                : 25 mM 
pH-adjustment to 7.3 with NaOH  
Partricin                            : 500 μg/L 
Penicillin/Streptomycin : 105 U/L 
Collagenase mixture Prepared in HDB+ Buffer 
Collagenase                    1000 units/ml 
Trypsin inhibitor               100 µg/ml 
Hyaluronidase                  1 mg/ml 
BSA                                  4 mg/ml 
DNAse II                           5 µl/ml 
Tumor medium 500 ml DMEM (4,5 g/l Glucose, +Gln) 
+ 50 ml FCS, heat-inactivated 
+ 5 ml Glutamine solution 
+ 5 ml Penicillin/streptomycin solution 
+ 5 ml Amphotericin B solution 
+ 5 ml MEM-vitamins solution 
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2.2.3 Plasmids 
 
 
Table 4: Plasmids. 
Plasmid Origin 
ß-Galaktosidase D. Spengler, Max-Planck-Institut für 
Psychiatrie, Deutschland 
CRE-luc Clontech Laboratories Inc., Palo Alto, 
CA, USA 
Flag-SIRT1 Addgene. M. Greenberg; Brunet, 
Cambridge, MA, USA 
rGH-luc Gutierrez-Hartmann, University of 
Colorado, USA 
 
 
2.2.4 Cell-lines 
 
In this study, GH3 cell lines from rats (American Type Culture Collection) were used. 
The cells were cultured in tumor medium at 37 ° C in a humid atmosphere with 5% 
CO2. When confluence was reached, cells were washed with PBS, trypsinized and 
centrifuged at 1200 x g for 4 minutes. Finally, they were seeded into multiwell plates 
for the respective experiment. 
 
 
2.2.5 Primary cell cultures of human GH-secreting pituitary adenomas 
 
In this part of the study, with approval of the Ethics Committee of the Max Planck 
Institute, GH-secreting pituitary adenomas from 7 patients were examined. From 
every patient, or their relatives, informed consent was given. The tumors were 
diagnosed using clinical, radiological, surgical and biochemical findings. 
Transsphenoidal surgery was the resection method of choice. According to the 
classification of Hardy, pituitary adenomas are subdivided in microadenomas (<1 cm) 
and macroadenomas (> 1 cm).  
After surgical excision, the tumors were immediately given in cooled tumor medium 
and further processed within 24 hours. For this purpose, the tumor was washed with 
HDB+ buffer, whereupon fibers and deposits were removed and the tumor was 
divided into two pieces. For morphological analysis, some of the tumor was frozen 
with dry ice. The other part of the tumor was either frozen for RNA and protein 
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extraction or processed as follows for cell culture: After mechanical division into small 
fragments and processing with a collagenase mixture, the cells were counted, mixed 
in tumor medium to achieve the appropriate cell density and seeded into multiwell 
plates for the respective experiment. To identify possible resection-related 
contamination with normal anterior pituitary cells, an RT-PCR was performed using 
specific primers for SF-1 (steroidogenic factor 1). Expression of SF-1 is found only in 
the gonadotrophic cell lineage of the anterior pituitary (Zafar et al., 1995). When the 
expression of SF-1 is detected, it indicates the presence of normal anterior pituitary 
cells in the tumor material. SF-1 positive tumors were not included in this study.  
 
 
2.2.6 Transfection 
 
Transfection of the cells was carried out with SuperFect (Qiagen, Hilden, Germany). 
Cells (3 x 105) were transfected for 3 hours with 1 µg Flag-SIRT1 and 0,5 µg GH-luc, 
and left for 48 hours in 2 % FCS DMEM. The dual luciferase reporter assay 
(Promega) was used according to the manufacturer's instructions and the luciferase 
activity was determined by Berthold TriStar luminometer. For effective control of 
transfection, 0.3 μg plasmids were added with the Rous sarcoma virus promoter. 
This promoter drives the β-galactosidase gene.  
The following procedure was carried out to measure the activity of β-galactosidase: 
30 μg of distilled water was added to 20 μg of supernatant and finally spread to a 96 
well plate. Thereupon, 50 μg of ONPG buffer (2x) were pipetted into the mixture.  
At 37° C the 96-well plate was incubated in a light-protected container until the 
individual "wells" (shaft) showed a light yellow colour. The β-galactosidase activity 
was then measured in an ELISA plate reader at 420 nm. The values represent the 
ratio of the relative luciferase activity of the plasmids to the β-galactosidase activity.  
 
 
2.2.7 Plasmid preparation 
 
Competent Top10 bacteria (Invitrogen, Paisley, UK) were transformed with the 
desired plasmid (see table) according to insctructions of the manufacturer and 
applied to a LB agar of a petri with 50 μg/μL ampicillin. The petri was incubated 
overnight at 37 ° C. A single colony was removed from the plate and placed in a 250 
mL LB medium containing 50 μg / μL ampicillin. Overnight the colony was incubated 
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at 37 ° C. The plasmid was purified using Qiagen HiSpeed Purification System 
(Qiagen, Hilden, Germany). The rGH-luc construct has the proximal rat GH promoter 
upstream  of the reporter gene luciferase. The cAMP response element is located 
above the TATA box of the thymidine kinase promoter of the herpes simplex virus 
and the reporter gene luciferase in the CRE-luc construct (Mercury pathway profiling 
system, Clontech Laboratories, Inc., Palo Alto, CA). 
 
 
2.2.8 GH determination 
 
Rat lactosomatotroph GH3 cells were placed in 96 well plates (1x104 cells / well) with 
10% FCS DMEM medium. After 24 hours, the cells were treated with octreotide 
and/or metformin for 24 hours in a 0% FCS DMEM medium. After completion of the 
treatment, the supernatants of the individual wells were collected and stored frozen 
for rat GH measurement. Human somatotrophinoma cells were seeded into 48 well 
plates (1x105 cells/well) in tumor medium. After 48 hours of incubation, the cells were 
treated with octreotide and/or metformin for 24 h and then the cell culture 
supernatants were collected and frozen for later human GH analysis  
In GH3 cell culture supernatants, rat GH (rGH) was measured by radioimmunoasay 
(RIA) as described (Monteserin-Garcia, 2013). In this assay, radioactively labelled 
rGH (125I-rGH; BIOTREND, Cologne, Germany) competes with non-radioactive rGH 
in the cell culture sample for binding to a primary specific anti-rGH antibody. After 
addition of a secondary antibody and precipitation of the immunocomplex with 6% 
PEG, the radioactivity of the precipitate was measured with a gamma-counter and 
rGH concentrations in the samples could be calculated by comparing them with a 
standard curve made with different concentrations of a rGH standard.    
The human GH (hGH) concentration in the cell culture supernatants was determined 
with IMMULITE 2000 Growth Hormone, which is a solid-phase, two-site 
chemiluminescent immunometric assay (Monteserin-Garcia et al., 2013). In this 
assay, a solid phase (bead) covered with monoclonal anti-hGH antibodies binds the 
hGH of the sample. A second antibody also against hGH but containing the enzyme 
alkaline phophatase is added to the reaction mixture and forms an antibody-
sandwich complex with the solid phase and the hGH. After washing the antibody 
excess by centrifugation, a chemiluminescent substrate is added to the reaction. The 
intensity of the signal is proportional to hGH concentration. 
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3. Results 
 
3.1 Clinical Study 
 
3.1.1 Patient group 
 
The 49-membered group consisted of 26 men and 23 women. Mean age at diagnosis 
was 48 years. In the male group, diagnosis was made on average at 44.5 years and 
in the female group at 53.2 years. At the time of data collection, average age of male 
patients was 55.7 years and that of women 63.9 years.  
Furthermore, there were differences in tumor size, therapy form and therapy 
response.  
In our patient group, 35 patients had a diagnosed macroadenoma and 9 patients had 
a microadenoma. No information about tumor size was available in a total of 4 
patients. 
A total of 18 patients developed pituitary insufficiency during the course of their 
disease. In our patient cohort, 12 of the 49 (24.5%) patients had diabetes mellitus 
and all of these patients were treated with Metformin 
 
Table 5: Study cohort. 
  
 
Patients                         
          
                               n =  
Total 49 
Females 23 
Males  26 
  
Median age at diagnosis years = 
Entire group 48  
Females  
 
53,2 
Tumor Size n = 
Makro 35 
Mikro 9 
n.a. 4 
  
Treatment n = 
Surgery 
- Total 
- Primary therapy                                                         
 
45 
39 
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Somatostatin analogues 
- Total 
- Primary therapy 
 
36 
11 
Pegvisomant 
Dopamine agonists 
Radiotherapy 
4 
4 
13 
 
Biochemical control 
after SSA-Therapy 
 
 
normalized hormone values (%) 
Growth hormone 
IGF-1 
0.611 
0.472 
 
Hypopituitarism 
 
n = 
Total 
Women  
Men 
18 
3 
15 
Insufficiency 
- gonadotropic 
- thyreotropic 
- corticotropic 
 
15 
8 
6 
Hormone replacement 
- Sex hormones 
- Glucocorticoids 
- Thyroid hormones 
 
Metformin treated DM2 
 
23 
22 
29 
   
                                n = 
Patient cohort  
Patients with SSA-Therapy  
12 
8 
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3.1.2 Therapy modalities 
 
In 45 patients (92 %), transsphenoidal surgery was performed and 35 of these 
patients received this as primary therapy. Somatostatin analogs were applied in 36 
patients. In eleven patients, this was used as a primary therapy. In 36 patients, 
somatostatin analogue therapy was initiated and 11 patients received it as primary 
therapy.  
In addition to transsphenoidal surgery and somatostatin analog therapy, some 
patients were also used for other types of therapy. Radiotherapy was performed 
postoperatively in 13 patients. A total of four patients received an additional therapy 
with Pegvisomant and another four patients were treated with a dopamine agonist.  
 
 
3.1.3 Hypopituitarism 
 
In the patient group, 18 patients were affected by hypopituitarism, of which n=15 
were men and n=3 were women.  
In 15 patients, gonadotropic axis was affected, thyreotropic axis in eight, and 
corticotropic axis in six patients. Nine patients had an isolated disorder of one of the 
axes. In most patients, however, there was a combined insufficiency of several axes. 
In patients with hypopituitarism, glucocorticoids, sex hormones and thyroid 
hormones, either individually or in combination, were used therapeutically. A total of 
23 patients (47 %) received sex hormones, 22 patients (45 %) glucocorticoids and 29 
patients (59 %) thyroid hormones. 
 
Binary logistic regression (SPSS software) showed that there is no significant 
correlation between factors such as sex, age, duration of the disease, tumor size, 
SSA therapy, transsphenoidal operation, and the incidence of hypopituitarism.  
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Table 6: Correlation between different 
variables and hypopituitarism. 
  
 p-value 
Gender 0.16 
Age 0.439 
Duration of disease 0.378 
Tumor size 0.814 
SSA-Therapy 0.710 
Thranssphenoidal surgery 
 
0.541 
 
 
 
 
Of 36 patients who received SSA therapy, 15 patients were treated with 
corticosteroids. In seven patients normalization of the IGF-1 was observed during the 
course of the study. A linear regression analysis could not establish a correlation 
between decreasing IGF-1 by SSA therapy and treatment with corticosteroids (p = 
0.173). From the group of patients treated with SSA, 15 patients received additional 
therapy with testosterone and estrogen preparations. Four of these patients showed 
a normalization of IGF-1. The linear regression analysis showed no correlation 
between decreasing IGF-1 by SSA therapy and treatment with estrogens / 
progestogens and androgens (p = 0.085). From the group of patients who received 
SSA, 19 patients were additionally treated with thyroxine. In nine of these patients, 
IGF-1 decreased to normal levels. However, no correlation between treatment with 
thyroxine and decreasing IGF-1 in SSA therapy could be demonstrated within the 
framework of linear regression analysis (p = 0.721). A further regression analysis 
also showed no correlation between decreasing IGF-1 after SSA therapy and 
substitution treatment with corticosteroids, testosterone or L-thyroxine (VIF <3). 
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3.1.4 SSA-Therapy effect and the influence of Metformin 
 
In a large number of 36 patients treated with SSA, hormone levels were normalized. 
Overall, the GH value was normalized in 22 patients (61.1 %) and the IGF-1 value in 
17 patients (47.2%). 
 
Gender (p = 0.775) and duration of disease (p = 0.827) did not show a statistically 
significant correlation with decreasing IGF-1 in somatostatin analog therapy after 
performing a linear regression analysis. However, age (p = 0.075) showed a trend 
towards statistical significance.  
 
In 8 of the 36 patients (22.2 %) treated with SSA, there was also diabetes mellitus, 
which was treated in all cases with Metformin. 
 
In linear regression analysis, a correlation between metformin therapy and IGF-1 
levels could be shown during concurrent therapy with SSA (p = 0.031; R-square 
change: 0.135; R-square: 0.321). In patients who received metformin in addition to 
SSA therapy, there was a stronger suppression of IGF-1 values (see Figure 8). 
 
 
Figure 8: Stronger reduction of IGF-1 levels under therapy with metformin during 
concurrent therapy with somatostatin analogues. 
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3.2  In vitro studies: Influence of Metformin on GH-synthesis  
 
3.2.1 Metformin inhibits GH secretion in immortalized Rat-GH3-cells 
 
To determine whether metformin inhibits the secretion of GH on pituitary level, rat 
GH3 cells were treated for 24 h with increasing concentrations of metformin. 
Metformin dose-dependently inhibited GH secretion and thus showed a direct effect 
on GH production by lactosomatotroph tumor cells (Figure 9). 
 
Figure 9: Increasing concentrations of metformin lead to an inhibition of GH (in % of 
control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 44	
3.2.2 Metformin inhibits GH promoter activity 
 
To test the possibility that metformin inhibits GH production by impairing GH 
promoter activity and thus GH mRNA synthesis, GH3 cells were transiently 
transfected with a plasmid containing the luciferase gene downstream from the GH 
promoter (GH-luc). Treatment with metformin suppressed the activity of the GH-
promoter suggesting that Metformin lowers GH secretion by directly inhibiting its 
transcription. 
 
 
Figure 10: Metformin has an inhibitory effect on GH promoter activity (in % of 
control). 
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3.2.3 Influence of metformin on GH secretion in human somatotroph tumors  
 
To confirm that metformin also inhibits GH secretion by human somatotroph tumors, 
metformin (500 µM, 1000 µM) was added to primary cell cultures of 7 human 
somatotroph adenomas. 24 h treatment of the tumors with metformin in a 
concentration of 500μM resulted in a slight but not yet significant suppression of GH 
compared to untreated cells in all adenoma cell cultures studied. In contrast, 1000μM 
metformin significantly reduced GH production in all somatotroph adenoma cell 
cultures as shown in a representative example in figure 11.  
 
 
Figure 11: Metformin significantly suppresses GH secretion in a human somatotroph 
adenoma cell culture at a concentration of 1mM (64±13% vs. basal=100%). 
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3.2.4 Effects of combined metformin and octreotide treatment on GH secretion 
by human somatotroph adenomas 
 
To study the effect of metformin on octreotide-mediated suppression of GH secretion 
in human somatotroph adenomas, 7 primary cell cultures of somatotroph tumors 
were treated for 24 h with octreotide (1 nM) and metformin (500 µM) either alone or 
in combination. Whereas neither treatment with octreotide nor with metformin alone 
had a significant effect on GH secretion, combined octreotide/metformin application 
significantly suppressed GH release in all human somatotroph adenoma cell cultures 
studied as shown by a representative example (Figure 12). The data suggest that 
metformin has an additive suppressive effect on octreotide-mediated GH inhibition.   
 
Figure 12: In vitro studies on 7 human acromegaly tumors. Metformin significantly 
enhances the GH suppressive effect of octreotide (% of control 63 ± 13 versus 81 ± 
12). 
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4. Discussion 
 
This study aimed to investigate the effects of different therapeutic modalities on the 
outcome of the treatment of acromegaly with the somatostatin analogue octreotide. 
Both the interference with hormone replacement therapy and with anti-diabetic 
metformin treatment was investigated. For this purpose, a combined clinical and - in 
case of metformin - an in vitro study were carried out. 
 
In the clinical part of the study a retrospective data analysis was performed. In 
contrast to prospective studies, it is possible to obtain the results of data analysis in a 
shorter period of time as the data have already been measured and collected.  
In this study, all results were based on already collected data from patients with 
acromegaly that where included in the NeoExNetM database. Due to the typical 
nature of retrospective studies corresponding known difficulties were encountered, 
for instance incomplete or scarce patient data. Despite uniform criteria of the 
NeoExNetM, the data of the patients were variable because patients have come to 
control examinations with varying degrees of frequency and different forms of the 
disease. For this reason, visits, blood sampling, functional tests and other entered 
data varied. It is shown in Table 1, that there was a broad range of data for our 
patients, which could theoretically have been included in the study. However, data 
and information were lacking in many patients and therefore not all patients had data 
on the individual parameters from Table 1. We opposed this with conscientiousness 
and selective exclusion of non-significant data sets. Therefore we only used data that 
were available for a sufficient number of patients and were therefore accessible for 
statistical analysis. Table 5 gives a good overview about the data which were 
available in most patients and could therefore be examined. Nevertheless, it is 
important to emphasize that the results of the study must be viewed critically, since 
as already mentioned a lot of the data showed a considerable degree of variation, in 
particular the dosages of medication and the treatment periods. 
 
In the following, patient data from our study are compared with data from larger 
epidemiological studies. In our cohort of 49 patients the male/female distribution was 
almost identical which has also been described in literature (Lavrentaki, Paluzzi, 
Wass, & Karavitaki, 2017). It is worth mentioning that in our cohort women received 
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the diagnosis of acromegaly on average a little later than men. This has also been 
reported in other epidemiological studies (Fernandez et al., 2010; Lavrentaki et al., 
2017).  
With regard to the development of pituitary insufficiency, it is worth mentioning that in 
this study the prevalence of hypopituitarism was slightly higher than described in 
common literature (Mestron et al., 2004). In a large-scale study investigating the 
prevalence and incidence of hypopituitarism in the general population, a lack of LH / 
FSH was most common and in most cases three or more hormones were deficient 
(Regal, Paramo, Sierra, & Garcia-Mayor, 2001). This is comparable with our patient 
group where the LH / FSH axis was also most frequently affected. 
Transsphenoidal surgery and radiotherapy are the most common risk factors for 
developing hypopituitarism. In contrast, the pre- or postoperative treatment of the 
patients with somatostatin analogues, growth hormone receptor antagonists or 
dopamine agonists do usually cause no pituitary insufficiency (Melmed, 2006; 
Prabhakar & Shalet, 2006). However, this study did not show any correlation 
between patient characteristics like gender, age, disease duration, tumor size as well 
as therapy modality and the development of hypopituitarism. Nonetheless, it is quite 
possible that one of these factors could have led to pituitary insufficiency, but due to 
our small cohort statistically no significant correlation could be established. 
 
It is known that resistance to therapy during treatment with SSA is a problem in some 
patients with acromegaly. For this reason, it was important to see how many patients 
would achieve biochemical control under SSA therapy. The percentage of patients in 
this study that achieved normalization of GH and IGF-1 levels was slightly below the 
remission rates reported in the literature (Melmed, 2006). Due to this relatively 
frequent resistance to somatostatin analogue therapy in some patients, we also 
wanted to know whether there are any other drugs that are already used in the 
treatment of acromegaly and its comorbidities and may have a positive influence on 
the effectiveness of SSA. 
As mentioned, hormone replacement is used for the treatment of hypopituitarism in 
acromegalic patients with one or more disturbed hormone axes. In this context a 
disturbed hypothalamic-pituitary adrenal axis may be most critical as the affected 
acromegalic patients receive cortisone, which is believed to have an inhibitory effect 
on the somatostatin type 2 receptor (Petersenn, Rasch, Presch, Beil, & Schulte, 
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1999). For this reason, it was of particular interest to find out whether the treatment 
with hormone substitutes such as cortisone had an influence on the effectiveness of 
SSA therapy in our patient cohort. The statistical tests, that were carried out showed 
that treatment with corticosteroids or any other kind of hormone replacement had no 
effect on the responsiveness of SSA therapy in terms of IGF-1 values in patients with 
acromegaly. Thus, although this has to be confirmed in larger studies, there was no 
evidence for an effect of hormone replacement therapy on the efficacy of SSA 
treatment in patients with acromegaly.    
 
In our study cohort, about a quarter of patients with acromegaly also suffer from 
diabetes mellitus type 2 and are usually treated with metformin. Statistical analysis of 
patient data showed that treatment with metformin lead to significant lower IGF-1 
values in patients treated with SSA. It was also shown that patient’s age also played 
a role in patients treated with regard to lower IGF-1 values. In statistical analysis 
patient’s age showed a trend towards statistical significance, what is in line with a 
publication that assumes that IGF-1 values depend partly on age (Franco et al., 
2014). However, other factors not considered in this study could have also led to a 
reduction in IGF-1 levels. Systemic diseases including a catabolic metabolism, liver 
or kidney failure and malnutrition can lower IGF-1 levels and lead to false-negative 
IGF-1 levels (Katznelson et al., 2011). 
The observation that metformin may improve the inhibitory action of SSAs in the 
treatment of acromegalic patients is new, but is in line with studies in which it was 
shown that in addition to its antidiabetic action, metformin probably has also other 
potentially useful effects. It has been reported that metformin reduces the risk of 
developing cancer in patients with diabetes mellitus type 2 (Evans, Donnelly, Emslie-
Smith, Alessi, & Morris, 2005; Hawley et al., 2003; Lizcano et al., 2004; Musi et al., 
2002). This effect of metformin is linked with its direct effect on tumor cells and its 
ability to keep insulin levels low by inhibiting gluconeogenesis and promoting glucose 
uptake in muscles (Dowling, Niraula, Stambolic, & Goodwin, 2012). For instance, 
potential antitumor activity of metformin is mainly due to activation of AMP-activated 
protein kinase, which is a promising factor in therapy of tumor diseases as a sensor 
of energy levels of the cell (Ben Sahra, Le Marchand-Brustel, Tanti, & Bost, 2010; G. 
Zhou et al., 2001). Another potentially useful effect of metformin could be an 
improvement in atherosclerosis (Forouzandeh et al., 2014). However, presumed 
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positive effects on blood pressure have not yet been demonstrated (Snorgaard, 
Kober, & Carlsen, 1997).  
 
The in vivo findings about the enhanced inhibitory action of SSAs in acromegalic 
patients treated with metformin prompted me to investigate in the second part of my 
thesis the action of metformin on GH secretion alone and in combination in vitro. To 
this end the lactorsomatotroph GH3 rat pituitary cell line, which is a classical model to 
study the regulation of GH synthesis and secretion, was used to investigate the effect 
of metformin on GH promoter activity and GH secretion. Subsequently, a small series 
of primary cell cultures obtained from human somatotroph tumor tissues was used to 
prove the GH inhibitory effect of metformine alone and in combination with octreotide 
in human somatotroph tumor cells.  
Metformin suppressed GH promotor activity in GH3 cells, which means that it inhibits 
GH mRNA synthesis. Moreover, metformin dose-dependently suppressed GH 
secretion in GH3 cells and within 24 h the highest metformin dosage applied (1 µM) 
led to a nearly 50% reduction of GH secretion. As GH3 cells may contain 
considerable amounts of GH, the rapid inhibitory effect on GH release may not only 
be explained by its suppressive effect on GH mRNA synthesis but may indicate that 
metformin acts in parallel also on the GH secretory machinery. The underlying 
molecular and cellular mechanisms of metformin on GH synthesis and secretion 
have not further been studied as this would have been far beyond the scope of a 
medical thesis.  
Metformin alone also dose-dependently suppressed the GH secretion in human 
somatotroph adenoma cell cultures. When applied together with octreotide, an 
additive inhibitory effect of the two compounds was observed which would support 
the in vivo findings in acromegalic patients in which a stronger GH suppression was 
achieved in the subgroup of diabetic patients that received both octreotide and 
metformin in comparison to non-diabetic acromegalic patients that were treated with 
octreotide alone.   
 
When starting to write the present thesis, a paper was published by An and 
colleagues, in which the effect of metformin on GH production by GH3 cells and 
human somatotroph tumor cells has also been studied (An et al., 2017). Using five 
times higher dosages of metformin as applied in the present thesis, they also showed 
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that metformin inhibited GH secretion by somatotroph tumor cells, but did not study 
its effect on the GH promoter and in combination with octreotide (An et al., 2017). 
They focused their interest on the growth inhibitory role of metformin and could show 
that metformin inhibited the proliferation and stimulated the apoptosis in somatotroph 
tumor cells both in vitro in cell cultures but also in vivo in experimental GH3 tumors in 
nude mice suggesting that metformin has a more general anti-tumorigenic role in 
somatotroph tumors (An et al., 2017). Their findings were in part confirmed in a very 
recent study, in which it was demonstrated that the growth both of GH3 cells and 
GH1 cells, another somatotroph rat pituitary tumor cell line, could be inhibited by 
metformin (Faggi et al., 2018). The anti-tumorigenic action of metformin was also 
demonstrated very recently in another pituitary tumor cell type, in corticotroph AtT20 
mouse pituitary tumor cells. In this cell type metformin inhibited proliferation, induced 
apoptosis and suppressed ACTH production (Jin et al., 2018). However, due to its 
known effects on metabolic mechanisms it is unclear whether metformin will be used 
as a drug for the treatment of pituitary adenomas or other types of tumors responding 
to metformin in the future. But it is also evident that patients with diabetes type 2 will 
not only benefit from the anti-diabetic action of metformin but in addition from its anti-
tumorigenic effects.     
 
With respect to the putative mechanisms of action of metformin on GH production, it 
is necessary to keep in mind how metformin operates within the cell and how these 
mechanisms interfere with the signaling pathways regulating GH synthesis and 
secretion. One of the biomolecular functions of metformin is inhibition of Complex I of 
the mitochondrial respiratory chain in liver cells (Wheaton et al., 2014). This results in 
reduction of ATP-synthesis and reduction of chemical energy within the cell which 
leads to activation of AMP-activated protein kinase A (Stephenne et al., 2011). AMPK 
is known as a sensor of energy balance within the cell and plays an important role in 
inhibition of gluconeogenesis (Hardie, 2011; Jeon, 2016). Suppression of 
gluconeogenesis through metformin results on the one hand by an inhibition of the 
adenylate cyclase by reduction of ATP and on the other hand by induction of Sirt1 
after increased expression of the AMP-activated protein kinase (Caton et al., 2010; 
Viollet et al., 2012).  
It has been shown that energy sensors within the cell could have an effect on 
endocrine and metabolic processes and the energy sensors AMPK and Sirt1 are of 
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particular interest here. In a current study, AMPK has been investigated as a 
potential target in the therapy of GH secreting pituitary tumors (Faggi et al., 2017). It 
has also been shown that AMPK influences the function in somatotrophic cells by 
inhibiting the growth of pituitary adenoma cells and their secretion of growth hormone 
(Tulipano et al., 2011). Another study showed that Sirt1 inhibits the GH/IGF-1 axis by 
inhibiting the GH secretion at pituitary level (Monteserin-Garcia et al., 2013).  
 
To understand the context, it is important to illustrate the intracellular processes of 
GH synthesis and the transcription factor CREB. GHRH binds to somatotroph cells 
via the GHRH-receptor, a stimulatory G protein-coupled receptor that is 
predominantly expressed in somatotroph cells of the pituitary gland (Mayo et al., 
2000). After binding to the G protein-coupled receptor, an increase in cAMP results 
and activation of the protein kinase A occurs. Possibly, PKA enters the nucleus and 
activates the transcription factor CREB which is responsible for GH transcription 
(Cohen, Hashimoto, Zanger, Wondisford, & Radovick, 1999). Subunits of PKA 
activate the co-activator of transcription, the CREB binding protein (CBP). Activated 
CBP is mobilized by the DNA binding proteins Pit1 and CREB to the GH-promoter 
(GH-luc) where expression of GH takes place (Monteserin-Garcia et al., 2013). In 
contrast, GH secretion was shown to decline by the activation of the regulatory 
enzyme Sirt1 and the subsequent inhibition of CREB and Pit1 (Monteserin-Garcia et 
al., 2013). It was demonstrated, that activation of Sirt1 led to an inhibition of GH-luc 
(GH promoter) and an inactivation of Sirt1 led to an increased activity of the promoter 
(Monteserin-Garcia et al., 2013). 
In contrast to GHRH, that activates cAMP/PKA, somatostatin suppresses through 5 
different somatostatin receptors (SSTR1 to SSTR5) the production of cAMP and 
down-regulates PKA expression and activity (Theodoropoulou & Stalla, 2013). 
Somatostatin binds to its receptors that are linked to inhibitory G-proteins. The latter 
suppress the adenyl cyclase activity which reduces intracellular cAMP levels and 
thus suppress the subsequent cAMP signaling cascade including CREB 
phosphorylation and activation. In this context octreotide is mainly acting through the 
SSTR2 and SSTR5 (Theodoropoulou & Stalla, 2013). Thus octreotide and metformin 
affect GH Production in somatotroph tumor cells through different pathways, 
octreotide through inhibiting the cAMP/PKA pathway and metformin through 
activating AMPK/Sirt1 signaling. The independent GH inhibitory effects of octreotide 
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and metformin may explain their additive GH-suppressive effect when applied 
together. 
 
However, very recently an alternate GH-suppressive action of metformin has been 
suggested in which this compound is inhibiting GH production through suppressing 
STAT3 phosphorylation (An et al., 2017). Only a couple of years ago, it was shown 
that in somatotroph pituitary adenoma cells, STAT3 upregulation induces GH 
hypersecretion through mechanisms that are not yet completely understood. 
Consequently, STAT3 inhibitors were able to reduce GH secretion in vitro in human 
somatotroph adenoma cell cultures and in GH3 cells as well as in vivo in 
experimental GH3 tumors in nude mice (C. Zhou et al., 2015). When studying the 
mechanism of action of metformin in GH3 cells, An and colleagues could show, that 
the effects of metformin on proliferation/apoptosis and on GH secretion are mediated 
through two different mechanisms (An et al., 2017). Whereas the effects of metformin 
on GH3 cell proliferation and apoptosis involved AMPK activation, the suppressive 
action of metformin on GH secretion was mediated through down-regulation of 
STAT3 phosphorylation (An et al., 2017).         
 
For this reason, it is actually not yet completely clear, whether the inhibitory effect of 
metformin on the secretion of GH and consequently IGF-1 is triggered by the 
activation of energy sensors such as AMPK and Sirt1 or whether the effect is 
mediated through STAT3 inhibition. Thus more work is needed to clarify the precise 
mechanism of action of metformin. However, as our clinical results suggest that the 
combined application of metformin and octreotid lowers IGF-1 levels significantly 
better than octreotide alone in acromegalic patients, future studies on the role of 
metformin on GH suppression are recommended to improve the treatment of patients 
with acromegaly.  
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5. Summary 
 
Somatostatin analogues (SSA) constitute the mainstay of pituitary-targeted 
pharmacological treatment in acromegaly, but half of the patients are resistant to 
their anti-secretory and tumor shrinking effects. The successful management of 
acromegaly in addition to targeting biochemical control involves the treatment of the 
metabolic comorbidities and hypopituitarism that is managed with hormone 
replacement. The aim of this study was to analyze the impact of the concomitant 
antidiabetic treatment with metformin and hormone replacement on the response to 
SSA. Data were collected from 49 acromegalic patients: 45 had transsphenoidal 
surgery (35 as primary therapy), 36 SSA (octreotide or lanreotide; 11 as primary 
treatment). All acromegalic patients with diabetes mellitus (25%) received metformin. 
Hypopituitarism affected 18 patients. Binary logistic regression analysis (SPSS 
software) showed no correlation between SSA (p=0.71) and transsphenoidal surgery 
(p=0.541) on the incidence of pituitary insufficiency. Regression analysis showed no 
correlation between IGF-1 lowering response to SSA and substitution treatment with 
hydrocorticosterone, testosterone, or L-thyroxin (variance inflation factor <3). Linear 
regression analysis showed no correlation between age, gender, disease duration, 
other treatment modalities (hydrocorticosterone, testosterone, or L-thyroxin) and 
change of IGF-1 levels after SSA treatment. However, the same analysis showed 
correlation between metformin therapy and IGF-1 levels after SSA treatment 
(p=0,031; R-square change: 0,135; R-square: 0,321). In a series of in vitro 
experiments, metformin alone significantly suppressed GH secretion at the 1mM 
concentration (64±13) and similar observations were obtained on the rat GH 
promoter activity and GH secretion from rat immortalized GH-secreting GH3 cells. In 
vitro investigation on 7 human acromegalic tumours showed that metformin (500nM) 
enhances the GH-suppressive effect of octreotide (1nM) (63±13% versus 81±12). 
These preliminary observations indicate that hormone replacement does not affect 
SSA response, but metformin treatment improves SSA response in terms of IGF-1 
reduction most likely through directly suppressing GH production in somatotroph 
tumor cells. 
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6. Zusammenfassung 
Somatostatin-Analoga (SSA) sind bei weitem die wichtigsten Medikamente bei der 
pharmakologischen Behandlung der Akromegalie, jedoch sind die Hälfte der 
Patienten resistent gegen ihre antisekretorischen und tumorschrumpfenden Effekte. 
Die erfolgreiche Behandlung der Akromegalie beinhaltet neben der klinischen 
Kontrolle zusätzlich die Behandlung von Komorbiditäten, u.a. Diabetes Typ 2 und 
Hypophyseninsuffizienz, welche mit Metformin bzw. Hormonersatzmedikamenten 
therapiert werden. Ziel dieser Studie war es, die Auswirkungen der begleitenden 
Therapie mit dem Antidiabetikum Metformin und Hormonersatzmedikamenten in 
Hinblick auf die Wirkung von GH-inhibierenden SSA zu untersuchen. Es wurden von 
49 Patienten mit Akromegalie Daten erhoben. 35 dieser Patienten erhielten eine 
transsphenoidale Operation als primäre Therapieform. 36 Patienten erhielten SSA in 
Form von Octreotide oder Lanreotide und 11 aus dieser Gruppe erhielten SSA als 
primäre Therapie. Alle akromegalen Patienten mit Diabetes mellitus erhielten 
Metformin (25%). Bei 18 Patienten wurde eine Hypophyseninsuffizienz festgestellt. 
Mittels SPSS Software wurde eine binäre logistische Regressionsanalyse 
durchgeführt, welche keine Korrelation zwischen der SSA-Therapie (p=0.71) und 
transphenoidaler Operation (p=0.541) im Hinblick auf die Inzidenz einer 
Hypophyseninsuffizienz offenbarte. Die Regressionsanalyse wies keinen 
Zusammenhang zwischen sinkenden IGF-1-Werten bei SSA-Therapie und der 
Behandlung mit Hormonersatzmedikamenten wie Hydrocortison, Testosteron oder L-
Thyroxin bei Hypophyseninsuffizienz auf (Variance inflation factor < 3). Bei der 
linearen Regressionsanalyse konnte keine Korrelation zwischen Alter, Geschlecht, 
Erkrankungsdauer und anderen Therapieformen wie Hydrocortison, Testosteron oder 
L-Thyroxin im Hinblick auf sinkende IGF-1-Werte bei SSA Therapie festgestellt 
werden. Jedoch zeigte die gleiche Analyse eine Korrelation zwischen Metformin-
Therapie und IGF-1-Werten nach SSA-Therapie (p=0,031; R-square change: 0,135; 
R-square: 0,321). In vitro Untersuchungen in somatotropen GH3 Tumorzellen 
zeigten, dass Metformin (1 mM) alleine die GH-Sekretion signifikant supprimierte 
(64±13%) und die Aktivität des GH-Promotors inhibierte. In vitro Untersuchungen an 
7 akromegalen Tumoren zeigten, dass Metformin (500 nM) die GH-suppressive 
Wirkung von Octreotide (1nM) verstärkt (63±13% vs. 81±12%). Diese 
Beobachtungen zeigen, dass der Hormonersatz die SSA-Wirkung nicht beeinflusst, 
während Metformin die SSA-Wirkung im Hinblick auf IGF-1-Reduktion verbessert.  
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